Ocumetics to Present Clinical Program Updates at ASCRS Annual Meeting

Calgary, Canada — April 1, 2026 — Leads & Copy — Ocumetics Technology Corp. is set to engage with potential strategic partners and key industry stakeholders at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C.

The leadership team of Ocumetics (TSV:V OTC) (OTCQB: OTCFF) (FRA: 2QBO), a next-generation ophthalmic technology company, will be providing updates on its First-in-Human (FIH) clinical program and outlining the next phase of its clinical development strategy.

The company will present the latest results from its ongoing FIH clinical study, evaluating the Ocumetics Lens, its accommodating intraocular lens technology. Discussions will cover early surgical outcomes, patient response, key learnings informing the study's expansion, and recent Ocumetics Lens design advancements.

Ocumetics will also provide an update on its planned Group 2 surgeries, representing the next stage of patient enrollment in the FIH clinical study. These procedures are expected to further evaluate the performance and consistency of the Ocumetics Lens and provide additional clinical data to support the company’s broader regulatory and commercialization strategy.

According to Dean Burns, President and CEO of Ocumetics, the company is known for pushing the boundaries of ophthalmic innovation. He said the Group 1 surgeries provided valuable insights into the surgical performance and patient outcomes of the Ocumetics Lens. Burns added that the meetings at ASCRS will allow them to share these learnings directly with potential strategic partners as they prepare for the next phase of the clinical program, including Group 2 surgeries.

The ASCRS annual meeting is a major gathering of ophthalmic surgeons, researchers, and medical technology companies, providing a key forum for presenting new technologies and discussing advancements in cataract and refractive surgery.

Ocumetics believes collaboration with surgeons, researchers, and industry partners will be critical as the company advances the Ocumetics Lens technology through clinical development and toward global commercialization.

Ocumetics Technology Corp. is focused on developing advanced vision correction solutions. The Canadian research and product development company aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses, and without perceptible time lag. Ocumetics is in the first-in-human early feasibility study phase of this technology.

Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts.

Source: Ocumetics Technology Corp.